Medicinal Cannabis in New Zealand is a new industry. Cannasouth is a leading NZ company dedicated to developing medicinal cannabis products. This page contains information on medicinal cannabis products that meet the medicinal cannabis minimum quality standard. Helius Therapeutics is a biotechnology company focused on medicinal cannabis research and development in Auckland, New Zealand
Next-Generation Medicinal Cannabinoid Therapeutics
Cannasouth was New Zealand’s first medicinal cannabis company to list on the New Zealand Stock Exchange (NZX:CBD) in June 2019. We are a vertically integrated biopharmaceutical company dedicated to advanced product development and research. Our goal is to develop next-generation medicinal cannabis products for prescribers and patients in New Zealand and export these pharmaceutical quality products and technologies globally.
We will produce our cannabis-based medicines and ingredients using cannabinoid extracts from high-quality, medical-grade cultivars. These medicines will be manufactured under GACP and GMP regulations using environmentally friendly methods, ensuring patients are treated with sophisticated medicines made of pure therapeutic compounds of the highest quality.
Cultivation Facility Achieves Good Agricultural and Collection Practice (GACP) Certification
NZX Virtual Investor Event
Cannasouth research shows cannabinoids could provide relief from debilitating neuropathic pain
Medicinal Cannabis Industry Update
Cannasouth Limited released a Medicinal Cannabis Industry Update in June 2021.
This update is designed to share information about the emerging medicinal cannabis industry both in New Zealand and globally; the opportunities and challenges facing industry players, the New Zealand regulatory environment, and the barriers to entry.
The PDF is available to view and download at the following link:
The New Zealand and Global Medicinal Cannabis Industry Update.
CCL First Harvest
CCL First Commercial Crop
CCL Commissioning complete
Cannasouth provides clinical data, educational material and media for health care professionals enabling informed patient treatment choices.
Supporting patient access to high-quality educational material regarding cannabinoid therapeutics is central to meaningful health outcomes.
Our investors are critical to the success of the company. We acknowledge the special trust they place in us with our commitment to the expansion of Cannasouth.
Medicinal cannabis products that meet the minimum quality standard
13 September 2022: New medicinal cannabis products have been verified as meeting the minimum quality standard – Read more.
Generally, medicinal cannabis products are only available, on prescription, if they have:
- been assessed by the Medicinal Cannabis Agency as meeting the minimum quality standard under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, or
- obtained consent for distribution under the Medicines Act 1981 (approved and provisionally approved medicines)
Any doctor can prescribe a product listed here. A specialist recommendation and Ministerial approval are not required. For more information on a particular product, please contact the listed product supplier or manufacturer.
Medicinal cannabis products that meet the minimum quality standard under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019
The minimum quality standard is used to verify medicinal cannabis products which have been derived from the Cannabis plant. Synthetic CBD and THC products are unable to be verified to meet the minimum quality standard as they are not derived from the Cannabis plant.
Products that are listed as having been verified as meeting the minimum quality standards are unapproved medicines – there has been no assessment of their safety or efficacy. Being listed here does not guarantee that these products are currently available in New Zealand. Contact the licence holder to obtain the most up-to-date information on product availability.
Dosage Products – Prescription Medicine
The products listed in the following tables are categorised by their verified dosage form. The products have been verified as meeting the testing requirements and microbiological contamination limits applicable to the dosage form as listed.
Looking for Medicinal Cannabis information?
The Ministry of Health maintains a list of Medicinal Cannabis Products verified as meeting their minimum quality standard.
Helius is the proud Sponsor of MCinfo.com – New Zealand’s medicinal cannabinoid information service.
Unleashing the extraordinary potential of cannabis
to improve quality of life.
Helius Therapeutics is a GMP certified biotechnology company focused on medicinal cannabis research and development. We have designed and built a state-of-the-art facility in Auckland with controlled growing systems, integrated extraction site, advanced cannabinoid research laboratories and manufacturing operations. As regulatory reforms sweep across the world, Helius is prepared to set the standard for safe and effective medicinal cannabis products, made in New Zealand.
A world where medicinal
cannabis has become the
new normal in treating
conditions with proven
efficacy, advancing health
for all humanity.
Helius Therapeutics has a bold vision, to become a world leader in the research, development and production of next-generation cannabinoid medicines. Our team is innovating to create the world’s safest and most efficacious cannabis-based medicines